Keith Wilner

6PUBLICATIONS

37CO-AUTHORS

Predictive and prognostic markersToxicology (incl. clinical toxicology)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Jul 02, 2026

Clinical validation of tissue and liquid companion diagnostics for BRAF V600E detection in non-small cell lung cancers from the PHAROS study.

|Apr 01, 2026

Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation.

Jeremy A Bartlett, Natalie Culver, Matt Santangelo

|Oct 19, 2025

Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.

Melissa L Johnson, Egbert F Smit, Enriqueta Felip

|Dec 17, 2021

Encorafenib plus binimetinib in patients with <i>BRAF</i><sup>V600</sup>-mutant non-small cell lung cancer: phase II PHAROS study design.

Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip

|Sep 22, 2020

Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population.

Kazuhiko Nakagawa, Koichi Matsumura, Tayler Scory

|Sep 02, 2020

Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival.

MeganS Farris, Kelly A Larkin-Kaiser, Tayler Scory

Pageof 1

Frequent Collaborators

3 joint publications

Anne Tsao

3 joint publications

Gregory J Riely

2 joint publications

Kelly A Larkin-Kaiser

Tayler Scory

Bruce E Johnson

Jasmina I Ivanova

Myung-Ju Ahn

Enriqueta Felip

Suresh S Ramalingam

Egbert F Smit

Frequent Collaborators

3 joint publications

Anne Tsao

3 joint publications

Gregory J Riely

2 joint publications

Kelly A Larkin-Kaiser

2 joint publications

Tayler Scory